Paul L. Chazot
University of Sunderland
School of Sciences
Sunderland
Tyne and Wear SR2 7EE
United Kingdom
Name/email consistency: high
- The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies. Chazot, P.L. Curr. Med. Chem. (2004)
- British Neuroscience Association--17th National Meeting: 13-16 April 2003, Harrogate, UK. Chazot, P. IDrugs (2003)
- Studies on the subtype selectivity of CP-101,606: evidence for two classes of NR2B-selective NMDA receptor antagonists. Chazot, P.L., Lawrence, S., Thompson, C.L. Neuropharmacology (2002)
- Spreading depression-induced preconditioning in the mouse cortex: differential changes in the protein expression of ionotropic nicotinic acetylcholine and glutamate receptors. Chazot, P.L., Godukhin, O.V., McDonald, A., Obrenovitch, T.P. J. Neurochem. (2002)
- Safinamide (Newron Pharmaceuticals). Chazot, P.L. Curr. Opin. Investig. Drugs (2001)
- Overview: H3 histamine receptor isoforms: new therapeutic targets in the CNS?. Chazot, P.L., Hann, V. Curr. Opin. Investig. Drugs (2001)
- British Pharmacological Society/The Physiological Society--joint meeting. Advances in glutamatergic pharmacology. Chazot, P.L. IDrugs (2001)
- CP-101606 Pfizer Inc. Chazot, P.L. Curr. Opin. Investig. Drugs (2000)
- Neurotransmitter receptors and Parkinson's disease. Chazot, P. IDrugs (2000)
- British Pharmacological Society Cambridge Symposia. Pharmacology for the next millennium. 5-7 January 2000, Cambridge, UK. Chazot, P. IDrugs (2000)
- British Pharmacological Society--summer meeting. Chazot, P. IDrugs (1999)